Danaher and Microsoft: Bringing Agentic AI Into the Lab

Soon after announcing its partnership with NVIDIA to advance autonomous science, Danaher has now partnered with another giant of the technology world: Microsoft.
The strategic partnership aims to develop intelligent scientific instruments and an interoperable agentic ecosystem connecting technologies across Danaher's businesses, while remaining open to the wider laboratory environment.
By combining Danaher's scientific, workflow and instrumentation expertise with Microsoft's AI technologies, they hope to help scientists move more quickly from scientific hypotheses to experimental evidence.
At its heart is the development of a common agentic platform for instrument control and insight generation. By connecting instruments, data and laboratory workflows, Danaher and Microsoft want to make experimental processes more streamlined, with AI helping researchers interpret results and determine the next steps in an experiment.
Julie Sawyer Montgomery, President and CEO of Danaher, summarises the partnership’s aim to expedite scientific discovery in a LinkedIn post discussing the partnership.
“Behind every experiment is someone waiting for science to move faster,” she writes.
“Together, we’re developing instruments designed to help scientists interpret results, identify problems in real time and recommend what to test next. By connecting these technologies across the lab, what scientists learn from one experiment can help inform the next.
“ We’re developing instruments designed to help scientists interpret results, identify problems in real time and recommend what to test next. ”
“This is innovation at the speed of life: bringing together the best of Danaher to help researchers get from question to answer more quickly, so they have more time to make discoveries that improve lives.”
Danaher says initial commercial applications stemming from the partnership will reach customers before the end of the year, while “next-generation, agent-enabled instruments” are planned for 2027.
- 83% less time: Novice scientists completed an AI-assisted Leica microscope experiment up to 83% faster in preliminary internal testing.
- 68% fewer steps: The AI-assisted experiment required up to 68% fewer steps than the conventional approach.
- Four key capabilities: Agentic AI will support experimental planning, instrument control, real-time result interpretation and next-step recommendations.
- 2026 commercial rollout: Initial applications, including Molecular Devices' MetaXpress Acquire AI Assistant, are expected to reach customers before the end of 2026.
- 2027 instrument development: Danaher plans to introduce next-generation, agent-enabled scientific instruments in 2027.
Demonstrating time savings through agentic AI
Danaher and Microsoft have already published preliminary figures highlighting the potential efficiency benefits of AI-assisted scientific workflows.
In internal testing, novice scientists conducting an AI-assisted experiment on a Leica microscope took up to 83% less time and required up to 68% fewer steps to complete the experiment than novice scientists working without the AI assistant.
The researchers also produced high-quality data and completed the experiment in a time comparable to an expert.
While the results are preliminary and internally generated, they demonstrate how agentic AI could help reduce the complexity of scientific processes, particularly for less experienced users, while making specialist expertise more accessible.
Danaher's intelligent instruments are being designed to support scientists across four critical activities:
- Experimental planning: Translating scientific intent into experimental plans, instrument setup and methods.
- Instrument control: Operating hardware within defined safety boundaries and with user oversight, while guiding execution and troubleshooting.
- Real-time interpretation: Analysing results and identifying potential quality issues as experiments progress.
- Next-step recommendations: Suggesting corrective actions and subsequent experiments for scientists to review.
Importantly, the approach is designed to keep researchers involved in decision-making, with AI providing guidance and recommendations rather than removing scientific oversight.
“Danaher is building a common scientific agentic platform...that lets us deploy device-specific agents at scale across Danaher instruments, both at the edge, right at the instrument, and in the cloud,” writes Dr Luciano Lucas, Vice President and Enterprise Head of Autonomous and Intelligent Labs on LinkedIn.
He continues: “Today’s partnership is one part of our broader vision for autonomous science, alongside our first AI-powered autonomous lab and other technology partnerships. Together, they are building toward intelligent, connected systems that supercharge scientists and accelerate scientific discovery.”
Microsoft's growing presence in life sciences
For Microsoft, the partnership represents another opportunity to bring its AI infrastructure into scientific research and laboratory operations.
Azure and Microsoft Foundry will provide the underlying technology for Danaher's agentic ecosystem, with the latter enabling AI agents to interpret experimental results and guide instrument control.
Deb Cupp, Executive Vice President and Chief Revenue Officer at Microsoft Global Enterprise, says: “Danaher's scientific expertise, combined with Microsoft's AI platform, aims to give scientists more choice and control, and more time for discovery.
“This partnership aligns with our goal to help translate AI into real-world impact.”
It follows Microsoft’s partnership with German pharmaceutical firm Boehringer Ingelheim, which aims to explore how digital patient twins could transform clinical development, potentially improving trial design and accelerating the generation of evidence for new medicines.
Danaher - key partners
– NVIDIA: Danaher and NVIDIA are collaborating to advance autonomous science by combining Danaher's scientific instruments, laboratory workflows and automation technologies with NVIDIA's accelerated computing and AI capabilities. The partnership aims to connect AI models with real experimental data, helping researchers move faster from predictions to scientific evidence and develop increasingly intelligent laboratory environments.
– AstraZeneca: Danaher and AstraZeneca are working together to develop and commercialise novel diagnostic tools and tests designed to help clinicians identify patients most likely to benefit from precision medicines. The collaboration combines AstraZeneca's pharmaceutical expertise with Danaher's diagnostic technologies, including Leica Biosystems, to support the development of AI-powered diagnostics and more targeted treatment decisions.
– Microsoft: Announced in November 2026, the partnership combines Danaher's scientific and instrumentation expertise with Microsoft's AI technologies. Using Microsoft Azure and Microsoft Foundry, the companies are developing a common agentic platform to connect scientific instruments, interpret experimental results and guide laboratory workflows, with initial commercial applications expected before the end of 2026.



